Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654342 | 0.87 | DDB1 (0.59) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL19586745 | 0.87 | CRBN (0.76) | CRBNDDB1IKZF3 | |
| SCHEMBL3653606 | 0.87 | CRBN (0.59) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL13881359 | 0.87 | CRBN (0.59) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL3653400 | 0.87 | CRBN (0.59) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24132065 | 0.84 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL19954297 | 0.84 | CRBN (0.74) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL18596192 | 0.84 | CRBN (0.74) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL19586669 | 0.83 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1PARP1 | |
| SCHEMBL23979386 | 0.80 | DDB1 (0.51) | CRBNDDB1IKZF3ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619404-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-06-13 | — | — | US | disclosed |
| WO-2024107711-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | ADRM1, BRDT, RBX1 | CRBN 82/4885DDB1 144/4885IKZF3 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.